Respiratory syncytial virus hospitalizations among American Indian and Alaska native infants and the general United States infant population
Respiratory syncytial virus hospitalizations among American Indian and Alaska native infants and the general United States infant population
复制标题
DOI：
10.1542/peds.2004-0049
复制
发表时间：
2004-10-01
期刊：
影响因子：
8
通讯作者：
Anderson, LJ
中科院分区：
文献类型：
--
作者：
Holman, RC;Curns, AT;Anderson, LJ
Objective.通过检查呼吸道合胞病毒（RSV）相关的住院情况，确定美国印第安人（AI）和阿拉斯加原住民（AN）婴儿中呼吸道合胞病毒（RSV）疾病的负担。通过使用印度卫生服务/部落医院出院数据（AI/AN）和国家医院出院调查数据（美国普通人群），选择1997年至2001年因RSV诊断而住院的婴儿。2000 - 2001年，RSV疾病被列为所有AI/AN婴儿住院的14.4%的诊断，RSV感染引起的细支气管炎（12.2%）是前5名列出的诊断之一。对于AI/AN婴儿，RSV特异性住院率为每1000名婴儿34.4例住院，对于一般美国婴儿人群，为每1000名出生婴儿27.4例住院。居住在阿拉斯加和西南地区的AI/AN婴儿的住院率（每1000名婴儿分别有70.9和48.2例住院）远高于美国婴儿的总体住院率。RSV感染是美国所有婴儿住院的主要原因之一，生活在西南部和阿拉斯加地区的AI/AN婴儿与RSV感染相关的住院风险特别高。开发疫苗、抗病毒剂和其他预防RSV疾病的策略可能会产生重大的公共卫生效益。
Objective. To determine the burden of respiratory syncytial virus (RSV) disease among American Indian ( AI) and Alaska Native ( AN) infants, by examining RSV-associated hospitalizations.Methods. Infant hospitalizations from 1997 through 2001 with RSV listed as a diagnosis were selected by using Indian Health Service/tribal hospital discharge data for AIs/ANs and National Hospital Discharge Survey data for the general US population.Results. In 2000 - 2001, RSV disease was listed as a diagnosis for 14.4% of all AI/AN infant hospitalizations, with bronchiolitis attributable to RSV infection (12.2%) being among the top 5 listed diagnoses. The rate of RSV-specific hospitalizations was 34.4 hospitalizations per 1000 infants for AI/AN infants and 27.4 hospitalizations per 1000 births for the general US infant population. The hospitalization rates for AI/AN infants living in the Alaska and Southwest regions (70.9 and 48.2 hospitalizations per 1000 infants, respectively) were much higher than the overall rate for US infants.Conclusions. RSV infection is one of the leading causes of hospitalization among all infants in the United States, and AI/AN infants living in the Southwest and Alaska regions are at especially high risk for hospitalizations associated with RSV infection. Development of vaccines, antiviral agents, and other strategies to prevent RSV disease could yield substantial public health benefits.